// App-Quantinova.ai

: Bimekizumab comparative efficacy in psoriasis: Number needed to treat analyses of phase 3/3b trial data

Researchers

Presenter

  • Craig Leonardi

Principal Investigators

  • April Armstrong

  • Kilian Eyerich

  • Georgios Kokolakis

  • Nicola Tilt

  • Christopher Cioffi

  • Cynthia Madden

  • Natalie Nunez Gomez

  • Luis Puig

Medical Centers

  • Central Dermatology, St. Louis, MO

  • Keck School of Medicine of University of Southern California, Los Angeles, CA

  • Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany

  • Psoriasis Research and Treatment Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

  • UCB Pharma, Slough

  • UCB Pharma, Raleigh, NC

  • UCB Pharma, Monheim, Germany

  • Hospital de la Santa Creu Sant Pau, Universidad Autonoma de Barcelona, Barcelona, Spain

Locations

  • United States

  • Venezuela

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved